Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Inhibrx Biosciences, Inc. (INBX) had Normalized Income after Taxes of $-28.65M for the most recently reported fiscal quarter, ending 2025-06-30.
| Income Statement Financials | |
$1.30M |
|
$-28.65M |
|
-- |
|
$1.30M |
|
$28.69M |
|
$-27.39M |
|
$-1.26M |
|
$-28.65M |
|
$-28.65M |
|
$-28.65M |
|
$-28.65M |
|
$-28.65M |
|
|
Normalized Income after Taxes |
$-28.65M |
$-27.39M |
|
$-26.73M |
|
15.47M |
|
15.47M |
|
$-1.85 |
|
$-1.85 |
|
| Balance Sheet Financials | |
$193.96M |
|
$4.88M |
|
$18.15M |
|
$212.12M |
|
$38.94M |
|
$99.28M |
|
$104.62M |
|
$143.56M |
|
$68.56M |
|
$68.56M |
|
$68.56M |
|
14.48M |
|
| Cash Flow Statement Financials | |
$-65.85M |
|
$-0.02M |
|
$99.84M |
|
$152.60M |
|
$186.57M |
|
$33.97M |
|
$5.22M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.98 |
|
-- |
|
-- |
|
0.59 |
|
1.45 |
|
100.00% |
|
-2106.85% |
|
-2106.85% |
|
-- |
|
-2204.00% |
|
-2204.15% |
|
$-65.87M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
1.34 |
|
66.95 |
|
-41.79% |
|
-41.79% |
|
-13.51% |
|
-17.07% |
|
$4.74 |
|
$-4.26 |
|
$-4.26 |
|